New anemia tablets offer increased options
By Nho, Byung Chul | translator Kim, Jung-Ju
23.10.21 05:50:42
가나다라
0
EAS injections dominate the Korean market…top-line growth reaches KRW 100 billion
AZ’a ‘Evrenzo,’ JW’s ‘Enaroy,’ and Mitsubishi’s Vadanem were approved in 2021, 2022, and 2023, respectively
Identified efficacy and effect in clinical trial…significantly improved convenience in intake
Whether the introduction of tablet formulations that offer improved convenience in intake in the KRW 100 billion renal anemia treatment market will shift the market paradigm and offer new options for anemia patients is gaining attention.
Until now, erythropoietin stimulating agents were the mainstream treatment for anemia caused by chronic kidney disease, but in 2021, 2022, 2023, AstraZeneca·JW Pharmaceutical·Mitsubishi Tanabe Pharma Korea each received approval for their Evrenzo Tab(Roxadustat)· Enaroy Tab(Enarodustat)· Vadanem Tab(Vadadustat) from the Ministry of Food and Drug Safety, respectively, and showed the new potential held by hypoxia-inducible factor-prolyl hydroxylase inhibitors
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)